Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03407001 · ClinicalTrials.gov registry record · Early Phase 1
Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT03407001: Completed Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03407001 is a Early Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03407001, a Early Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This early phase I trial studies how well contrast enhanced ultrasound with sulfur hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Contrast enhanced ultrasound with Lumason may help doctors more easily find liver cancer compared to ultrasounds without contrast agent.
Interventions
- PROCEDURE Contrast-Enhanced Ultrasound
- DRUG Sulfur Hexafluoride Lipid Microspheres
- PROCEDURE Ultrasound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-01-12 |
| Est. Completion | 2020-09-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03407001
The ClinicalTrials.gov registry entry for NCT03407001 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Contrast-Enhanced Ultrasound is the first listed.
NCT03407001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03407001 about?
NCT03407001 is a clinical study titled "Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis". This early phase I trial studies how well contrast enhanced ultrasound with sulfur hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are injected into a vein in order to h...
What is the current status of trial NCT03407001?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2018-01-12. Estimated completion is 2020-09-15.
What interventions are being tested in trial NCT03407001?
The interventions under investigation include: Contrast-Enhanced Ultrasound (PROCEDURE), Sulfur Hexafluoride Lipid Microspheres (DRUG), Ultrasound (PROCEDURE).
Who is sponsoring clinical trial NCT03407001?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.